Free Trial

Medpace (MEDP) Stock Forecast & Price Target

$443.00
+8.01 (+1.84%)
(As of 07/12/2024 ET)

Medpace - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Consensus Price Target

$445.29
0.52% Upside
High Forecast$469.00
Average Forecast$445.29
Low Forecast$395.00
TypeCurrent Forecast
7/14/23 to 7/13/24
1 Month Ago
6/14/23 to 6/13/24
3 Months Ago
4/15/23 to 4/14/24
1 Year Ago
7/14/22 to 7/14/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
6 Buy rating(s)
6 Buy rating(s)
3 Buy rating(s)
1 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$445.29$443.14$382.00$241.00
Forecasted Upside0.52% Upside12.96% Upside6.77% Upside12.02% Upside
Get Medpace Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for MEDP and its competitors with MarketBeat's FREE daily newsletter.

MEDP Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

MEDP Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Medpace Stock vs. The Competition

TypeMedpaceMedical CompaniesS&P 500
Consensus Rating Score
2.86
2.71
2.50
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside0.52% Upside992.48% Upside9.38% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/8/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$456.00 ➝ $469.00+15.63%
5/29/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$452.00+15.66%
5/28/2024Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A. Hynes
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$435.00+11.38%
4/24/2024Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$453.00 ➝ $464.00+17.50%
4/23/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy$340.00 ➝ $450.00+19.60%
3/18/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageHold$395.00-0.44%
2/15/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$282.00 ➝ $452.00+15.96%
5/8/202322nd Century Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingUpgrade

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 02:05 AM ET.

MEDP Forecast - Frequently Asked Questions

What is Medpace's forecast for 2024?

According to the research reports of 7 Wall Street equities research analysts, the average twelve-month stock price forecast for Medpace is $445.29, with a high forecast of $469.00 and a low forecast of $395.00.

Should I buy or sell Medpace stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last year. There is currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" MEDP shares.

Does Medpace's stock price have much upside?

According to analysts, Medpace's stock has a predicted upside of 13.56% based on their 12-month stock forecasts.

Has Medpace been upgraded by Wall Street analysts recently?

Over the previous 90 days, Medpace's stock had 1 upgrade by analysts.

What analysts cover Medpace?

Medpace has been rated by research analysts at Guggenheim, Jefferies Financial Group, Mizuho, Robert W. Baird, and TD Cowen in the past 90 days.

Do Wall Street analysts like Medpace more than its competitors?

Analysts like Medpace more than other "medical" companies. The consensus rating score for Medpace is 2.86 while the average consensus rating score for "medical" companies is 2.71. Learn more on how MEDP compares to other companies.


This page (NASDAQ:MEDP) was last updated on 7/13/2024 by MarketBeat.com Staff

From Our Partners